Xaluritamig

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameXaluritamig
Drug Alias NameAMG-509
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD3Anti-STEAP1
TargetsT cell surface glycoprotein CD3Six-transmembrane epithelial antigen of the prostate 1
Therapy Area/IndicationsCastration-Sensitive Prostate NeoplasmsHormone-Sensitive Prostate NeoplasmsProstatic Neoplasms, Castration-Resistant +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[23] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAmgen IncXencor Inc
China Registration ClassN/A

Develop Information

Active CompaniesBeOne Medicines LtdAmgen IncBeOne Medicines (Beijing) Co Ltd
Inactive CompaniesN/A
Active IndicationsCastration-Sensitive Prostate NeoplasmsHormone-Sensitive Prostate NeoplasmsProstatic Neoplasms, Castration-Resistant +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A